June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Cannabinoid 2 (CB2) receptor upregulation in experimental autoimmune uveitis (EAU)
Author Affiliations & Notes
  • Gil Ben-David
    Ophthalmology, Rabin Medical Center, Petah Tikva, Israel
  • Yael Nisgav
    Ophthalmology, Rabin Medical Center, Petah Tikva, Israel
  • Yehonatan Weinberger
    Ophthalmology, Rabin Medical Center, Petah Tikva, Israel
  • Michal Kramer
    Ophthalmology, Rabin Medical Center, Petah Tikva, Israel
    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Footnotes
    Commercial Relationships   Gil Ben-David None; Yael Nisgav None; Yehonatan Weinberger None; Michal Kramer None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2227 – A0523. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gil Ben-David, Yael Nisgav, Yehonatan Weinberger, Michal Kramer; Cannabinoid 2 (CB2) receptor upregulation in experimental autoimmune uveitis (EAU). Invest. Ophthalmol. Vis. Sci. 2022;63(7):2227 – A0523.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To study the expression of CB2 receptor in the posterior segment of the eye and its response to intraocular inflammation (IOI).

Methods : EAU was induced in 53 C57BL/6J mice as previously published using the uveitogenic 161-180 amino acid fraction of human intra-retinal-binding-protein (hIRBP). Clinical and histopathological grading were performed on days 4, 10, 17, 21 and 24 post induction using indirect ophthalmoscopy and H&E staining respectively. CD4+ T Cells and CB2 receptor were stained in ocular sections and retinal whole flat mounts using immunofluorescence. Perfusion of Fluorescein isothiocyanate dextran conjugate (MW 500k, Sigma) was used for retinal blood vessels staining in flat retinas. Analysis was performed at different time points for cell volume and number using Confocal 3D microscopy and Imaris software.

Results : IOI occurred in 44 out of 53 (83%) mice with induced EAU. Clinical signs of inflammation appeared at 10 days, peaked at 17 to 21 days, and declined at 24 days, post EAU induction. Mice with high clinical scores exhibited more CD4+ cells and higher CB2 receptor positive cells in the vitreous, retina and choroid compared to mice with low grades of inflammation. In retinal flat mounts analysis, CB2 receptor was present in the retina of control mice and significantly upregulated on day 10 (p<0.05). CD4+ cells were located outside the retinal blood vessels, peaked on days 10-21 and diminished on day 24 post induction (p<0.05).

Conclusions : EAU proved to be a robust and reproducible model in our laboratory. CB2 receptor peaked in the retina earlier than the appearance of CD4+ cells which paralleled the clinical appearance of IOI. These preliminary results suggest that cannabinoids may have a potential effect on EAU.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

CB2 receptor significantly upregulated on day 10 post EAU induction.
*p<0.05

CB2 receptor significantly upregulated on day 10 post EAU induction.
*p<0.05

 

CD4+ cells peaked on days 10-21 and diminished on day 24 post EAU induction.
*p<0.05

CD4+ cells peaked on days 10-21 and diminished on day 24 post EAU induction.
*p<0.05

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×